OncoMatch/Clinical Trials/NCT06185751
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Is NCT06185751 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including WS-CART-CS1 and Lymphodepleting chemotherapy for multiple myeloma.
Treatment: WS-CART-CS1 · Lymphodepleting chemotherapy — Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor (bortezomib, carfilzomib)
including proteasome inhibitor (e.g. bortezomib or carfilzomib)
Must have received: anti-CD38 therapy (daratumumab)
anti-CD38 therapy (e.g. daratumumab)
Must have received: anti-BCMA therapy (BCMA bispecific antibodies, BCMA CAR-T)
anti-BCMA therapies (e.g. BCMA bispecific antibodies or BCMA CAR-T)
Cannot have received: systemic therapy
Any prior systemic therapy for multiple myeloma within 14 days before planned day of leukapheresis
Cannot have received: cellular therapy
Receipt of any cellular therapy within 8 weeks prior to the planned start of conditioning
Lab requirements
Kidney function
calculated creatinine clearance ≥ 50 mL/min/1.73 m2 OR radioisotope glomerular filtration rate ≥ 50 mL/min/1.73 m2 OR normal serum creatinine based on age/gender per institutional normal range
Liver function
ALT (SGPT) ≤ 5 x ULN for age; Total bilirubin ≤ 2.0 x IULN (unless the patient has Grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin)
Cardiac function
LVEF ≥ 45% confirmed by echocardiogram or MUGA within 28 days of screening
Adequate renal, hepatic, respiratory, and cardiovascular function, as defined below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify